BioCentury
ARTICLE | Clinical News

212Pb-TCMC-Trastuzumab: Phase I started

May 14, 2012 7:00 AM UTC

Areva Med LLC, Bethesda, Md. Product: 212Pb-TCMC-Trastuzumab Business: Cancer Molecular target: NA Description: Trastuzumab combined with lead-212 isotope Indication: Treat cancer that has metastasiz...